Immune modulation for the treatment of type 1 diabetes

Investigator: Jeffrey Bluestone, PhD
Sponsor: American Diabetes Association, Inc.

Location(s): United States


The project will focus on one of several areas of research in the Bluestone lab including: 1. Role of Tregs in b cell protection and tissue repair; 2. MicroRNA function in T cells; 3. Targeting CTLA-4 and PD-1 to induce tolerance to islet antigens; 4. Creating the perfect Treg for the treatment of diabetes. These efforts, as well as others available to the student will help elucidate the biological basis of immune tolerance and continue the firm commitment of the lab as an important catalyst for developing novel therapies for treating type I diabetes.